CD274 and non-small cell lung carcinoma: For advanced NSCLC with PD-L1 TPS > 50%, anti-PD-1, or anti-PD-L1 monotherapy is an option—with approvals for pembrolizumab, cemiplimab, or atezolizumab monotherapy.